Brandywine Global Investment Management LLC Has $19.77 Million Stake in DaVita Inc. $DVA

Key Points

• Brandywine Global Investment Management LLC increased its stake in DaVita Inc. by 19.3%, owning 129,219 shares worth $19.77 million after purchasing an additional 20,947 shares.
• DaVita reported earnings of $2.95 EPS, exceeding analysts' expectations of $2.70, while revenue rose 6.1% year-over-year to $3.38 billion.
• Hedge fund ownership of DaVita is substantial, with institutional investors holding 90.12% of the company's stock.

Brandywine Global Investment Management LLC increased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 19.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,219 shares of the company's stock after purchasing an additional 20,947 shares during the period. Brandywine Global Investment Management LLC owned approximately 0.17% of DaVita worth $19,767,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. UMB Bank n.a. boosted its holdings in DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after acquiring an additional 76 shares during the period. Copia Wealth Management bought a new stake in DaVita during the fourth quarter valued at about $30,000. National Pension Service boosted its holdings in DaVita by 74.3% during the first quarter. National Pension Service now owns 197 shares of the company's stock valued at $30,000 after acquiring an additional 84 shares during the period. Y.D. More Investments Ltd bought a new stake in DaVita during the first quarter valued at about $35,000. Finally, Coppell Advisory Solutions LLC boosted its holdings in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after acquiring an additional 100 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Insider Transactions at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by company insiders.

DaVita Price Performance

NYSE:DVA traded up $1.0340 during mid-day trading on Wednesday, hitting $137.7140. The company's stock had a trading volume of 222,788 shares, compared to its average volume of 862,088. DaVita Inc. has a fifty-two week low of $126.07 and a fifty-two week high of $179.60. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. The company has a market capitalization of $9.85 billion, a price-to-earnings ratio of 13.55, a P/E/G ratio of 0.95 and a beta of 1.09. The stock has a fifty day moving average of $139.55 and a 200-day moving average of $144.70.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the prior year, the business posted $2.00 earnings per share. The company's quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Ratings Changes

DVA has been the subject of a number of recent analyst reports. Barclays decreased their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Truist Financial set a $148.00 target price on shares of DaVita in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $164.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.